I'm LongbridgeAI, I can summarize articles.Revenue: As of FY2025 Q1, the actual value is USD 104.41 M.
EPS: As of FY2025 Q1, the actual value is USD -0.21.
Patient Services Segment
- Revenue: $53,068 for the three months ended March 31, 2025, compared to $52,453 for the same period in 2024, representing a 1.2% increase.
- Direct Costs: $47,080 for the three months ended March 31, 2025, compared to $49,497 for the same period in 2024, representing a 4.9% decrease.
- Operating Income: $4,515 for the three months ended March 31, 2025, compared to $1,723 for the same period in 2024.
Dispensary Segment
- Revenue: $49,293 for the three months ended March 31, 2025, compared to $39,679 for the same period in 2024, representing a 24.2% increase.
- Direct Costs: $39,863 for the three months ended March 31, 2025, compared to $32,809 for the same period in 2024, representing a 21.5% increase.
- Operating Income: $9,398 for the three months ended March 31, 2025, compared to $6,839 for the same period in 2024.
Clinical Trials & Other Segment
- Revenue: $2,045 for the three months ended March 31, 2025, compared to $2,534 for the same period in 2024, representing a 19.3% decrease.
- Direct Costs: $214 for the three months ended March 31, 2025, compared to $391 for the same period in 2024, representing a 45.3% decrease.
- Operating Income: $1,774 for the three months ended March 31, 2025, compared to $2,088 for the same period in 2024.
Cash Flow
- Net Cash Used in Operating Activities: -$4,988 for the three months ended March 31, 2025, compared to -$15,883 for the same period in 2024.
- Net Cash Used in Investing Activities: -$202 for the three months ended March 31, 2025, compared to $19,388 provided for the same period in 2024.
- Net Cash Used in Financing Activities: -$4,740 for the three months ended March 31, 2025, compared to -$938 for the same period in 2024.
Future Outlook and Strategy
- Core Business Focus: The company has implemented initiatives to reduce costs and more effectively manage working capital, resulting in an 11% reduction in SG&A expenses compared to the prior year same quarter.
- Non-Core Business: The company entered into a Research Services Agreement with Helios CR, Inc., effective May 5, 2025, where the Clinical Trials segment will be operated by Helios under a profit-sharing arrangement.